FY2028 EPS Estimates for argenex Boosted by Leerink Partnrs

Key Points

• Leerink Partners has increased its FY2028 earnings per share (EPS) estimate for argenex to $34.14, up from a previous forecast of $32.50, indicating strong financial expectations for the company.
• The company's stock has received multiple upgrades, with analysts maintaining a consensus rating of "Buy" and an average target price of $736.81.
• In its recent earnings report, argenex reported an EPS of $3.74 for the quarter, significantly exceeding analysts' expectations of $2.84.

argenex SE (NASDAQ:ARGX - Free Report) - Leerink Partnrs lifted their FY2028 EPS estimates for argenex in a research report issued on Thursday, July 31st. Leerink Partnrs analyst T. Smith now anticipates that the company will earn $34.14 per share for the year, up from their previous forecast of $32.50. The consensus estimate for argenex's current full-year earnings is $3.13 per share. Leerink Partnrs also issued estimates for argenex's FY2029 earnings at $40.74 EPS.

Several other brokerages also recently weighed in on ARGX. Wells Fargo & Company upped their target price on shares of argenex from $741.00 to $756.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. HC Wainwright increased their price target on shares of argenex from $720.00 to $774.00 and gave the company a "buy" rating in a report on Friday. Baird R W raised shares of argenex from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Robert W. Baird upgraded shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price objective on the stock in a research note on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a "hold" rating to a "buy" rating in a research report on Tuesday, July 8th. Nineteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $746.81.

argenex Price Performance

argenex stock traded down $15.42 during trading on Monday, reaching $674.90. 464,778 shares of the company were exchanged, compared to its average volume of 445,794. argenex has a 52-week low of $485.91 and a 52-week high of $696.21. The company has a market capitalization of $41.30 billion, a P/E ratio of 34.61, a PEG ratio of 0.86 and a beta of 0.39. The stock's 50 day simple moving average is $573.16 and its two-hundred day simple moving average is $596.64.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. The company had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%.

Institutional Trading of argenex

Institutional investors and hedge funds have recently modified their holdings of the business. GeoWealth Management LLC grew its holdings in argenex by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after buying an additional 18 shares in the last quarter. Greenleaf Trust boosted its stake in argenex by 3.5% during the first quarter. Greenleaf Trust now owns 624 shares of the company's stock valued at $369,000 after buying an additional 21 shares during the period. Rakuten Securities Inc. grew its position in argenex by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after buying an additional 22 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in argenex by 1.3% during the first quarter. Sequoia Financial Advisors LLC now owns 1,829 shares of the company's stock worth $1,083,000 after buying an additional 24 shares in the last quarter. Finally, M&T Bank Corp grew its position in argenex by 0.6% during the first quarter. M&T Bank Corp now owns 4,296 shares of the company's stock worth $2,542,000 after buying an additional 27 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.